The Wayback Machine - https://web.archive.org/all/20060318143618/http://search.messages.yahoo.com/search/messages?tag_M=Prostrate+Cancer&fname_M=txt_main
Search the web
Sign In
New User? Sign Up

click here


Yahoo! Message Boards
Help - Add To My Yahoo! - Sign In
Search Result:   Found 0 board match and 17 message match for [Prostrate Cancer]

Yahoo! Message Boards - Message Matches  (1 - 17 of 17)
Business & Finance > Investments > Sectors > Healthcare > Medical Equipment and Supplies > RITA
  • Re: Cancer can not stand the heat? - Sounds good but prostrate is not the target here due to obvious medical reasons... for now boobs and lungs are the next gold mine, g/l! - by: trader1987

    • Business & Finance > Investments > Sectors > Healthcare > Medical Equipment and Supplies > EDAP
  • Cancer cure!!!!!!!!!!!!!! Invest in it - No cure for any cancer will ever be 100% EDAP has a cure for prostrate cancer, 93% effective using a follow-up of PSA screening POST 5 YEARS. Relapse rate is 7%. Alternatives offer relapse rates between 15 to 30%. If you had prostrate cancer, which choice would you make. EDAP has 1% market penentration. THIS is why none of us should consider selling this stock for less than 1.5 Billion MC. Thats $203/share folks. We are on a ROCKETSHIP and someone just lit a match. - by: r201592002
  • Re: Cancer cure!!!!!!!!!!!!!! Invest in - prostate not "prostrate" - by: drlapinski
  • SIMPLE FACT - No cure for any cancer will ever be 100% EDAP has a cure for prostrate cancer, 93% effective using a follow-up of PSA screening POST 5 YEARS. Relapse rate is 7%. Alternatives offer relapse rates between 15 to 30%. If you had prostrate cancer, which choice would you make. EDAP has 1% market penentration. THIS is why none of us should consider selling this stock for less than 1.5 Billion MC. Thats $203/share folks. We are on a ROCKETSHIP and someone just lit a match. - by: r201592002

    • Business & Finance > Investments > Sectors > Healthcare > Biotechnology and Drugs > GNBT
  • CRAMER WILL PUMP INSM TONITE..!!!!! - EXXA AND INSM WILL BE MULTI-BAGGERS THIS YEAR....HERE'S WHY: **** EXXA 2.37.....ONLY 3.8M FLOAT: EXXA WILL REPORT RECORD REVENUES AND MOST LIKELY DOUBLE-DIGIT NET INCOME NEXT WEEK. I EXPECT NET INCOME OF OVER 50c/share IN 2006. EXXA's CEO BOUGHT ALMOST 200K SHARES IN THE OPEN MARKET IN LAST 4 MONTHS...HE ALREADY OWNED 52% BEFORE THAT!!! Exx Inc. (AMEX: EXXA or EXX/A) will report its 4Q 2005 and FY 2005 financial results in late March 2006. This quarter's numbers will start showing revenues From the two major contracts won from DaimlerChrysler (DCX) in mid 2005. DaimlerChrysler is now Exx Inc.'s largest customer. The new DaimlerChrysler's contracts will represent about 30 % of the total projected $160M - $180M/year EXXA revenues in 2006. EXXA's market cap in contrast is only $24 million!!! take a look at EXXA's chart!! http://stockcharts.com/gallery/?exx/a MORE DETAILS: http://exxatosix.blogspot.com/ *********** INSM @ $2.1 - WITH SALE OF EQUITY ANNOUNCED THIS WEK, INSM HAS $61M IN CAS - by: ivalexy
  • INSM $2.11 ON FIRE!!!...EXXA $2.3 UP !! - *********** INSM @ $2.10 - WITH SALE OF EQUITY ANNOUNCED THIS WEK, INSM HAS $61M IN CASH or 70c/Outstanding Share. - THE CURRENT NUMBER OF OUTSTANDING SHARES IS 88M INCLUDING THE 20M SHARES SOLD (per company filings). - INSM WILL LAUNCH ITS FIRST FDA-APPROVED DRUG IN 2Q 2006. INSM ALREADY OWNS THE MANUFACTURING PLANT AND HAS HIRED TOP-OF-THE LINE PERSONNEL. - HAS A RICH DRUG PIPELINE ADDRESSING AILIMENTS FROM CANCER, TO INSULIN RESISTANCE, TO MUSCULAR DISTHROPHY, TO MUSCLE/BONE WEAKNESS, TO HIV......etc...etc.... Insmed (Nasdaq: INSM) announced AH on Wednesday, March 15, that it had received net proceeds of approximately $42.8M from a stock offer. Originally it was estimated that INSM would only net $37.2M from the equity sale. INSM now has a solid balance sheet featuring over $60M in cash or about 70c per outstanding share. The company plans to use the funds to: *** Accelerate the comercial launch and manufacturing of iPlex, its first drug approved by the FDA. The company plans to launch  - by: ivalexy
  • INSM $2.03 WILL LAUNCH IPLEX IN 2Q 2006 - TARGET: $4+ IN JUNE........HERE IS WHY - WITH SALE OF EQUITY ANNOUNCED THIS WEEK, INSM HAS $61M IN CASH or 70c/Outstanding Share. - THE CURRENT NUMBER OF OUTSTANDING SHARES IS 88M INCLUDING THE 20M SHARES SOLD (per company filings). - INSM WILL LAUNCH ITS FIRST FDA-APPROVED DRUG IN 2Q 2006. INSM ALREADY OWNS THE MANUFACTURING PLANT AND HAS HIRED TOP-OF-THE LINE PERSONNEL. - HAS A RICH DRUG PIPELINE ADDRESSING AILIMENTS FROM CANCER, TO INSULIN RESISTANCE, TO MUSCULAR DISTHROPHY, TO MUSCLE/BONE WEAKNESS, TO HIV......etc...etc.... Insmed (Nasdaq: INSM) announced AH on Wednesday, March 15, that it had received net proceeds of approximately $42.8 million from the offering of 20M shares including an over-allotment of 3M shares. Originally it was estimated that INSM would only net $37.2M from the equity sale. The market rewarded INSM with a 4% gain after hours following the announcement. During the day, there was an obvious attempt to short/manipulate the stock price driving it down to a closing pr - by: ivalexy
  • INSM $2.08.. GETS FUNDING..UP FROM HERE - A FEW REASONS WHY INSM IS GOING UP AND WILL REACH $4+ IN JUNE 2006: - WITH SALE OF EQUITY ANNOUNCED YESTERDAY, INSM HAS $61M IN CASH or 70c/Outstanding Share. - THE CURRENT NUMBER OF OUTSTANDING SHARES IS 88M INCLUDING THE SHARES SOLD (per company filings). - WILL LAUNCH ITS FIRST FDA-APPROVED DRUG IN 2Q 2006. ALREADY OWNS THE MANUFACTURING PLANT AND HAS HIRED TOP-OF-THE LINE PERSONNEL. - HAS A RICH DRUG PIPELINE ADDRESSING ALIMENTS FROM CANCER, TO INSULIN RESISTANCE, TO MUSCULAR DISTHROPHY, TO MUSCLE/BONE WEAKNESS, TO HIV......etc...etc.... Insmed (Nasdaq: INSM) announced AH on Wednesday, March 15, that it had received net proceeds of approximately $42.8 million from the offering of 20M shares including an over-allotment of 3M shares. Originally it was estimated that INSM would only net $37.2M from the equity sale. The market rewarded INSM with a 4% gain after hours following the announcement. During the day, there was an obvious attempt to short/manipulate the stock price driving it down t - by: ivalexy
  • INSM $1.96..GETS FUNDING..MOVES FORWARD - NO MORE MONEY WORRIES......UP FROM HERE My Target: $3.5 - $4.5 by the end of June 2006 Insmed (Nasdaq: INSM) announced AH yesterday, that it had received net proceeds of approximately $42.8 million from the offering of 20M shares including an over-allotment of 3M shares. Originally it was estimated that INSM would only net $37.2M from the equity sale. The market rewarded INSM with a 4% gain after hours following the announcement. During the day, there was an obvious attempt to short/manipulate the stock price driving it down to a closing price of $1.96 for a loss of 5%. INSM now has a solid balance sheet featuring over $60M in cash or about 70c per outstanding share. The company plans to use the funds to: *** Accelerate the comercial launch and manufacturing of iPlex, its first drug approved by the FDA. The company plans to launch iPlex during 2Q 2006. *** Continue pursuing the marketing authorization for IPLEX in Europe. The company will submit a formal application to the EMEA (the European equival - by: ivalexy
  • Re: Curious about GNBT vaccine - As soon as the toxicology study is done, the full IND will be filed with the FDA. Time frame-90-120 days best estimate. It may be sooner considering that some of the work was already done at Walter Reed with tyhe breast and prostrate cancer vaccines. - by: digitaltradz

    • Business & Finance > Investments > Sectors > Technology > Electronic Instruments and Controls > TASR
  • EXXA $2.3. COULD TRIPLE AFTER EARNINGS - **** EXXA 2.37.....ONLY 3.8M FLOAT: EXXA WILL REPORT RECORD REVENUES AND MOST LIKELY DOUBLE-DIGIT NET INCOME NEXT WEEK. I EXPECT NET INCOME OF OVER 50c/share IN 2006. EXXA's CEO BOUGHT ALMOST 200K SHARES IN THE OPEN MARKET IN LAST 4 MONTHS...HE ALREADY OWNED 52% BEFORE THAT!!! Exx Inc. (AMEX: EXXA or EXX/A) will report its 4Q 2005 and FY 2005 financial results in late March 2006. This quarter's numbers could be huge because it will start showing revenues resulting from the two major contracts that the company won from DaimlerChrysler (DCX) in mid 2005. DaimlerChrysler is now Exx Inc.'s largest customer. The new DaimlerChrysler's contracts will represent about 30 % of the total projected $160M - $180M/year EXXA revenues in 2006. EXXA's market cap in contrast is only $24 million!!! take a look at EXXA's chart!! http://stockcharts.com/gallery/?exx/a MORE DETAILS: http://exxatosix.blogspot.com/ HERE IA ANOTHER TRUE GEM+++ *********** INSM @ $2.05 - WITH SALE OF EQUITY ANNOUNCED THIS WEK, I - by: ivalexy

    • Business & Finance > Investments > Sectors > Healthcare > Biotechnology and Drugs > HEB
  • INSM $2.05.. GETS FUNDING..UP FROM HERE - A FEW REASONS WHY INSM IS GOING UP AND WILL REACH $4+ IN JUNE 2006: - WITH SALE OF EQUITY ANNOUNCED YESTERDAY, INSM HAS $61M IN CASH or 70c/Outstanding Share. - THE CURRENT NUMBER OF OUTSTANDING SHARES IS 88M INCLUDING THE SHARES SOLD (per company filings). - WILL LAUNCH ITS FIRST FDA-APPROVED DRUG IN 2Q 2006. ALREADY OWNS THE MANUFACTURING PLANT AND HAS HIRED TOP-OF-THE LINE PERSONNEL. - HAS A RICH DRUG PIPELINE ADDRESSING ALIMENTS FROM CANCER, TO INSULIN RESISTANCE, TO MUSCULAR DISTHROPHY, TO MUSCLE/BONE WEAKNESS, TO HIV......etc...etc.... Insmed (Nasdaq: INSM) announced AH on Wednesday, March 15, that it had received net proceeds of approximately $42.8 million from the offering of 20M shares including an over-allotment of 3M shares. Originally it was estimated that INSM would only net $37.2M from the equity sale. The market rewarded INSM with a 4% gain after hours following the announcement. During the day, there was an obvious attempt to short/manipulate the stock price driving it down t - by: upsilontx

    • Business & Finance > Investments > Sectors > Capital Goods > Aerospace and Defense > BA
  • Re: 8 years and a pension - I don't know how appealing he'll be being how he has prostrate cancer. But I don't think the inmates at Club Fed are like that. He'll be out in less than three years when Bush gives him a medical pardon when he leaves office. - by: wildchinook

    • Business & Finance > Investments > Sectors > Healthcare > Biotechnology and Drugs > QGLY
  • R2, Stock pick of the month - No cure for any cancer will ever be 100% EDAP has a cure for prostrate cancer, 93% effective using a follow-up of PSA screening POST 5 YEARS. Relapse rate is 7%. Alternatives offer relapse rates between 15 to 30%. If you had prostrate cancer, which choice would you make. EDAP has 1% market penentration. THIS is why you should consider investing in this stock. This stock is a ROCKETSHIP and someone just lit a match. - by: r201592002

    • Business & Finance > Investments > Sectors > Healthcare > Biotechnology and Drugs > ANIK
  • OT -EDAP - No cure for any cancer will ever be 100% EDAP has a cure for prostrate cancer, 93% effective using a follow-up of PSA screening POST 5 YEARS. Relapse rate is 7%. Alternatives offer relapse rates between 15 to 30%. If you had prostrate cancer, which choice would you make. EDAP has 1% market penentration. THIS is why none of us should consider selling this stock for less than 1.5 Billion MC. Thats $203/share folks. - by: r201592002

    • Business & Finance > Investments > Sectors > Services > Business Services > VTIV
  • OT -EDAP - I boought VTIV at $5.50 several years ago, sold at $20 last year. Here is the most awesome pick I have ever found, including VTIV, GIVN and CTHR, and CRYP No cure for any cancer will ever be 100% EDAP has a cure for prostrate cancer, 93% effective using a follow-up of PSA screening POST 5 YEARS. Relapse rate is 7%. Alternatives offer relapse rates between 15 to 30%. If you had prostrate cancer, which choice would you make. EDAP has 1% market penentration. THIS is why none of us should consider selling this stock for less than 1.5 Billion MC. Thats $203/share folks. This stock is a ROCKETSHIP and someone just lit a match. - by: r201592002

    • Business & Finance > Investments > Sectors > Healthcare > Biotechnology and Drugs > GNVC
  • Re: This a $5 dollar stock now and $10 - True. The off label use could be huge. My mother died of pancreatic at 38 wish she had the opportunity to use TNFerade and have her tumor resectioned. 4 leading cancers are lung, colon, breast, and prostrate. There are many different solid tumor cancers that TNFerade could be beneficial for. - by: infinity_capital_group


    • All   Subject   Message Text   Authors  
    Copyright © 2006 Yahoo! Inc. All rights reserved.
    Privacy Policy - Terms of Service - Guidelines - Help